Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase EARLY_PHASE1 1

Status

Active not recruiting 2Completed 1

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Genitourinary 1Gastrointestinal 1Dermatologic 1

Conditions

Urinary Bladder Neoplasms 1Skin Neoplasms 1Pancreatic Neoplasms 1Melanoma 1Carcinoma, Transitional Cell 1

Interventions

pembrolizumab 1258Specimen Handling 864Carboplatin 824Magnetic Resonance Spectroscopy 806Cyclophosphamide 798Cisplatin 719Nivolumab 660Paclitaxel 635Gemcitabine 570Radiotherapy 570Biopsy 526Bevacizumab 467Dexamethasone 441fludarabine 403Docetaxel 375venetoclax 369Oxaliplatin 363Capecitabine 355Fluorouracil 354atezolizumab 337Rituximab 333durvalumab 332Doxorubicin 316Pemetrexed 306Radiosurgery 304Drug Therapy 300Ipilimumab 296Standard of Care 288Etoposide 283Radiation 277

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Interventional × urelumab × 1 year × Clear all
NCT02845323 2026-04-06

Neoadjuvant Nivolumab With and Without Urelumab in Cisplatin-Ineligible or Chemotherapy-refusing Patients With Muscle-Invasive Urothelial Carcinoma of the Bladder

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Phase 2 Active not recruiting
15 enrolled
Genitourinary

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

NCT02451982 2025-12-03

Platform Study of Neoadjuvant and Adjuvant Immunotherapy for Patients With Resectable Adenocarcinoma of the Pancreas

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Phase 2 Active not recruiting
76 enrolled
Gastrointestinal

Pancreatic Neoplasms

NCT02652455 2025-08-19

Combining PD-1 Blockade, CD137 Agonism and Adoptive Cell Therapy for Metastatic Melanoma

H. Lee Moffitt Cancer Center and Research Institute

Phase EARLY_PHASE1 Completed
11 enrolled
Dermatologic

Melanoma, Skin Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡